Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Long-term follow-up of people treated for severe aplastic anemia in an earlier trial

Follows people with severe aplastic anemia after they finished the earlier RACE trial.

Key facts

Who runs it
European Society for Blood and Marrow Transplantation
Where
Paris, FranceSee the site
Trial code
Registry title
RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
Status
Enrolling by invitation
People taking part
197 people, planned
Started
Oct 2021
Expected to end
Dec 2034
Type of study
Observational
Treatments tested
  • ATGAM plus CsA with or without Eltrombopag
Record updated
27 September 2021

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with severe aplastic anemia who took part in the earlier RACE trial (NCT02099747). It collects their health data over a long time.

Disease stage
Severe aplastic anemia.
Earlier treatment
People must have taken part in the RACE trial and received ATGAM and Cyclosporine A, with or without Eltrombopag.

Main reasons for not taking part

  • People who did not take part in the RACE trial cannot join.
  • People who do not agree to long-term data collection cannot join.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Subject participated in the RACE trial (NCT02099747, EudraCT number: 2014-000363-40) during which patient received ATGAM, Cyclosporine A with or without Eltrombopag
  • Subject has provided informed consent to participate in long-term data collection

Who cannot take part

  • None

Where in France

  • Hospital St. LouisParis, FranceNo longer taking part

About the trial

What the trial wants to find out

After exiting the RACE trial (NCT02099747) patients will be invited to participate in this long term follow-up study

The group in the trial

  • RACE 1 patients

    After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study

    Treatment: ATGAM plus CsA with or without Eltrombopag

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients
Plain-language title
Long-term follow-up of people treated for severe aplastic anemia in an earlier trialGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 September 2021